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The rapid growth of the global HIV/AIDS epidemic makes it a high priority to develop an effective vaccine. Since a live at-
tenuated or inactivated HIV vaccine is not likely to be approved for clinical application due to safety concerns, HIV virus like 
particles (VLPs) offer an attractive alternative because they are considered safer since they lack viral genome. We got a stable 
eukaryotic cell line by G418 resistance selection, engineered to express the HIV-1 structure protein Gag and Env efficiently 
and stably. We confirmed the presence of Gag and Env proteins in the cell culture supernatant and that they could 
self-assemble into VLPs. These VLPs were found to be able to elicit specific humoral and cellular immune response after im-
munization without any adjuvant. 
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The development of an effective, safe, and affordable vac-
cine for human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) is needed to control the 
worldwide HIV pandemic. At present, there is no vaccine 
against HIV approved for clinical use. There are three ob-
stacles that hinder creation of an HIV-1 vaccine: viral di-
versity, immune system evasion, and the lack of appropriate 
animal models for vaccine evaluation [1]. A major approach 
used to overcome viral immune evasion is to exploit the 
conserved regions of HIV-1 proteins, for example, the con-
served sites of envelope glycoprotein gp120 critical for 
binding to CD4 as well as co-receptors, or the envelope 
(transmembrane) protein gp41 co-receptor binding site 
[2–5]. Inducing production of broadly reactive Mabs could 
potentially counteract HIV-1 diversity. These two potential 
solutions of HIV-1 vaccine development could potentially 
be realized by exploiting prophylactic HIV-1 virus-like par-
ticle (VLP) vaccines [6].  
HIV-1 VLPs possess a complex structure based on viral 
gag proteins that self-assemble into particular structures 
analogous in size and morphology to immature HIV-1 parti-
cles. As non-infectious, replication-deficient particles, VLPs 
are much safer compared to traditional vaccines made by 
chemically inactivated or attenuated live viruses. The dif-
ferent forms of VLPs have distinct properties [7–10]. Only 
enveloped VLPs display full-length proteins with proper 
folding on their surface and closely mimic native envelope 
trimeric structures [7,11,12]. The immune system responds 
well to particular antigens that are similar to immature 
HIV-1 viruses [13]. VLPs antigens are processed and present 
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antigens through the major histocompatibility (MHC) class II 
pathway as well as the MHC class I endogenous pathway, 
inducing both CD4- and CD8-T-cell-mediated immune re-
sponses [14–16]. Therefore, VLPs can effectively induce 
both humoral and cellular immune reactions. It is also 
widely accepted that a rational vaccine design should have 
the potential to block the initial step of infection. In this 
respect, VLP-based vaccines are a promising type of re-
combinant protein vaccine.  
VLPs are now considered one of the most attractive can-
didate vaccines for HIV and multiple VLP-based vaccines 
for HIV-1 are currently under investigation [12,17–22]. 
However, it is still generally desirable to enhance VLP im-
munogenicity. In this study, we report the construction of 
VLPs by cotransfecting two kinds of plasmids into HEK293 
cells to obtain a mammalian cell line that efficiently and 
stably expresses the HIV-1 structural proteins Gag, pol, and 
Env. The VLPs induce specific humoral and cellular im-
mune responses after immunization, without any adjuvant. 
1  Materials and methods 
1.1  Materials 
Plasmid pcDNA3.1() and Lipofectamine-2000 were pur-
chased from Invitrogen (Carlsbad, CA, USA). The plasmids 
D-GPEi, pcDNA 3.1, EnvB/C, pNL4-3.Luc.R–E and 
HOS-CD4-CCR5 cells, HEK293 cells were obtained from 
our lab. The plasmids were purified using a Qiagen Plasmid 
Giga Kit (Qiagen, Venlo, Netherlands), and the final prod-
uct was endotoxin free (<2.5 units mg1). HIV-1 positive 
serum was obtained from a Guangxi AIDS patient. An-
ti-human-HRP-IgG was purchased from Jackson Immuno 
Research Laboratory, Inc. (West Grove, PA, USA) and 
G418 was purchased from Invitrogen. 
1.2  Production of recombinant HEK293 cells and 
HIV-1 VLPs 
Recombinant HEK293 cells expressing the HIV-1 structural 
proteins Gag and Env were obtained by cotransfecting 
plasmid D-GPEi and pcDNA3.1() into 293 cells. The 
plasmid D-GPEi was composed of the CMV promoter, a 
kanamycin resistance gene, prokaryotic cell high copy fac-
tors, and intron A. The main structural proteins Gag, pol 
and Env of a common China HIV-1 strain were cloned into 
this expression vector, with Gag fused to the N terminal of 
Pol as described [23]. All plasmid cloning was consistent 
with USA FDA clinical trial safety controls. Briefly, 
HEK293 cells were maintained in Dulbecco’s modified 
minimal essential medium (DMEM) supplemented with 
10% fetal calf serum (HyClone Laboratories, Logan, UT, 
USA). D-GPEi and pcDNA3.1() plasmids were cotrans-
fected into 293 cells using Lipofectamine-2000. Adherent 
G418 resistant cells were trypsinized and serial diluted into 
medium containing G418 48 h after transfection. Stable 293 
cell lines were maintained in standard growth medium with 
G418 (1 mg mL1). Cells were harvested and assayed by 
Western blot after 2–3 weeks to assess clonality. The posi-
tive supernatants were collected by centrifugation at 4000 r 
min1 for 30 min and passed through a 0.22 μm filter. VLPs 
were pelleted at 26000 r min1 for 1.5 h at 4°C in a Beck-
man SW28 rotor through a 30% sucrose cushion twice, and 
their assembly was confirmed by standard electron micros-
copy analysis and Western blot analysis. 
1.3  Immunization experiments 
Female BALB/c mice, in groups consisting of six animals 
6–8 weeks of age, were administered 0.5, 2.5, 12.5, and 25 
μg purified VLPs plus DNA (100 g) by intramuscular in-
jection. Control mice were treated with endotoxin-free 
phosphate-buffered saline (PBS). The immunization sched-
ule was based on a 3-dose regimen, where the boost inocu-
lations were administered at weeks 3 and 5 after the primary 
immunization. All immunization protocols were performed 
in two independent experiments without addition of adju-
vants. 
1.4  Sample collection and processing 
Blood samples were collected by tail bleeding from each 
animal one week after the last immunization. Serum was 
obtained by standard methods and stored at 80°C until use. 
1.5  TEM observation 
The VLPs were prepared by dropping the micelle solution 
on a copper grid. After a few minutes, excess solution was 
removed with a strip of filter paper. A JEOL-8100 electron 
microscope operated at 200 kV was used for transmission 
electron microscopy (TEM). 
1.6  Detection of cytotoxic T lymphocytes (CTL)  
Spleens from immunized mice were harvested two weeks 
after the fourth immunization. Approximately 1×106 
P815/BALB target cells were sensitized with synthetic pep-
tide at a concentration of 1 mmol L1, for 2 h at 37°C. Cy-
totoxicity was measured by a standard lactate dehydrogenase 
(LDH) release assay with a CTL kit (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. 
1.7  ELISPOT  
Splenic HIV-1 antigen-specific T cells were identified indi-
rectly using cytokine ELISPOT by measuring induced 
IFN- production (BD, Franklin Lakes, NJ, USA). Briefly, 
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nitrocellulose bottomed 96-well plates were coated over-
night with 5 g mL1 anti-IFN- antibody at 4°C, and non-
specific binding was blocked for 1 h at 37°C. Purified sple-
nocytes were dispensed in triplicate at a predetermined den-
sity. The plates were washed and the biotinylated detection 
antibody was added for another 1.5 h at 37°C. A 1/1000 
dilution of horseradish peroxidase-streptavidin was added to 
the wells and incubated for 1 h, after which horseradish 
peroxidase-streptavidin substrate was added. After 30 min, 
the colorimetric reaction was terminated by washing with 
tap water. The spots were counted after drying. 
1.8  Neutralization assays 
The plasmid pcDNA 3.1 EnvB/C and pNL4-3.Luc.R–E 
were cotransfected into 293T cells. Supernatants were col-
lected 48 h after transfection incubated with blood at a final 
dilution of 1:1, 1:2, 1:4 and 1:8 for 1 h at 37°C. The mix-
ture infected CD4-CXCR4-expressing HOS cells by DEAE. 
HOS cells were harvested, lysed, and tested after 72 h using 
the luciferase assay system (Promega) according to the 
manufacturer’s instructions. The extent of luciferase ex-
pression was quantitated in a Dynex MLX luminometer and 
recorded in relative light units (r.l.u.). An inhibitory neu-
tralization concentration, the concentration required to neu-
tralize the preincubation mixture, was calculated by linear 
regression analysis.  
1.9  Statistical analysis 
ANOVA (i.e., one-way ANOVA followed by Fisher’s LSD) 
was employed using SPSS 13.0 software. A P<0.05 was 
considered significant. All data points are presented as 
means±SE (standard error). 
2  Results 
2.1  Efficient expression of the HIV-1 gag, Pol, and env 
genes in 293 cells generates HIV-1 VLPs 
To generate a stable cell line expressing our genes of interest, 
we optimized the ratio of vector D-GPEi and pcDNA3.1 and 
determined a 3:1 ratio was optimal. We changed the selec-
tive media (G418) after 48 h and selected for positive colo-
nies that express the HIV-1 gag, pol and env structural pro-
teins, as determined by Western blot assays (data not 
shown). To test for secreted protein, cell supernatant was 
collected by 30% sucrose density centrifugation and pellets 
resuspended in PBS and assayed by SDS-PAGE and West-
ern blot (Figure 1). 
2.2  Stability of cellular expression 
We investigated the expression stability in the stable cell  
 
Figure 1  VLPs were prepared and analyzed by immunoblotting as de-
scribed in Materials and methods A, Immunoblot of purified VLPs using 
HIV-1-positive human serum. Lane 1, Mock supernatant; lane 2, purified 
VLPs. B, Lane 1, Mock; lanes 2–4, different positive cells and purified 
VLPs analyzed by immunoblotting with anti-p24 monoclonal antibody or  
polyclonal sheep anti-gp120 antibody. 
 
Figure 2  Immunoblot analysis of positive cell lines after 12 months. 
Lane 1, Cell lysis of mock transfected cells; lane 2, cell lysis after one  
month; lane 3, cell lysis after 12 months. 
line. Screened cell lines were maintained continuously in 
medium with G418. Expression of HIV-1 gagpol, and env 
protein were examined in cell lysate one month and 12 
months after transfection, respectively. Efficient expression 
of the target protein could still be detected in the cell lines 
after 12 months. HIV-1 VLPs could also be detected in cel-
lular supernatants of stable cell lines (Figure 2). 
2.3  Assembly of HIV-1 VLPs 
To investigate the synthesis and assembly of HIV-1 gagpol 
and env protein, we collected supernatant from positive 
cells by centrifuging at 26000 r min1 at 4C, for 4 h 
through a 10%–40% sucrose gradient. We found that the 
gagpol and env proteins passed through the lower density 
fractions and migrated to the 40% and 30% density layers. 
Western blot analysis indicated that protein could assemble 
into VLPs that included gagpol and env (Figure 3). 
2.4  VLPs morphology 
The MW of VLPs is too large to be analyzed by 
non-denaturing PAGE or by matrix-assisted laser desorption 
ionization/time of flight (MALDI-TOF) mass spectrometry. 
To confirm that Gag and Env were assembled into VLPs, 
we applied transmission electron microscopy (TEM) to su-
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pernatants obtained by ultracentrifugation through a 30% 
sucrose gradient cushion. This analysis showed that the 
proteins formed virus-like particle about 100 nm in diameter, 
and that the shape and the size were similar to that of a nat-
ural virus (Figure 4). 
2.5  HIV-1-specific humoral responses 
The sera specificity was evaluated by immunoblotting. The 
results presented in Figure 5 demonstrate that antibodies 
were induced in response to vaccination. New epitopes were 
not produced and no changes in immunodominance were 
detected. HIV-1-Gag-specific antibody responses from all 
VLPs treatments (2.5–25 g) were higher than that obtained 
for 100 g DNA (Figure 5A). In contrast, the HIV-1-Env-     
 
 
Figure 3  Gradient analysis of VLPs. Supernatant of positive cells was 
placed onto 30%–40% sucrose density gradients. Centrifugation was car-
ried out in a SW28 rotor at 4 and 100000×g for 4 h. Fractions were col-
lected from the bottom to the top (left to right) and analyzed by 
SDS-PAGE followed by Western blotting using anti-HIV-1 human serum. 
Lane 1, Marker; lane 2, fraction of bottom; lanes 3–6, 40%–10% gradient;  
lane7, supernatant layer. 
 
Figure 4  TEM image of VLPs. 
 
Figure 5 Western blot analysis of mouse serum antibody in response to 
HIV-1 Gag and Env protein. Mice sera collected after the third injection 
were tested at 1:20 dilution (pools of six). A, Lane 1, PBS group; lanes 
2–5, VLP 0.5, 2.5, 12.5, 25 g; lane 6, positive control; lane 7, DNA 100 
g. B, Lane 1, PBS group; lane 2, DNA 100 g; lanes 3–6, VLP 0.5, 2.5,  
12.5, 25 g; lane 7, positive control. 
specific antibody response from 0.5–25 g VLPs was about 
the same as that observed with 100 g DNA (Figure 5B). 
2.6  HIV-1-specific CTL responses 
VLPs are processed by antigen presenting cells (APCs) for 
MHC class I presentation to CD8+ cytotoxic T lymphocytes 
(CTL) [14]. To quantify the T-cell response, mice were in-
jected with VLP (0.5, 2.5, 12.5, and 25 g) and DNA (100 
g) using a 3-dose regimen. One week after the last injec-
tion, HIV-1-specific CD8+ T cells were measured in vitro 
by assessing the cell death of P815/BALB target cells, sen-
sitized with an H-2d-restricted CTL epitope. The CTL re-
sponse was low in the 0.5 g and DNA group, but increased 
in a dose-dependent manner. The highest CTL response was 
observed at 12.5 g (Figure 6), indicating that the CTL 




Figure 6  Analysis of splenic mononuclear cells cytolytic activity har-
vested from immunized mice. P815 mastocytoma cells (pool of six) pulsed 
with epitope were used as targets. Percent specific lysis was determined by  
a 4 h LDH-release assay. 
2.7  Vaccination enhances HIV-1 specific CTL as indi-
cated by IFN- ELISPOT 
During natural infection, HIV-specific Th1 cells, CTLs, and 
associated antiviral cytokines (IFN-, TNF-, IL-2) play 
key roles in virus recognition [24]. HIV-1-specific CD8+ T 
cells were measured in vitro by determining splenic IFN- 
production in response to brief re-stimulation with CTL 
epitopes, as measured by ELISPOT. The results indicate 
that the IFN- response to VLPs immunization at 25 g was 
the same as that for 12.5 and 0.5 g, and 2.5 g was also 
lower than 12.5 g, indicating that 12.5 g was needed to 
induce a cellular immune response in mouse (Figure 7). 
2.8  VLPs induce neutralizing antibody and alter anti-
body levels  
The plasmid pNL4-3.Luc.R–E contains luciferase and the full 
HIV-1 genome of except for a frameshift mutation in the Env 
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gene. The 293 T cells expressed constitutive Gag and Env 
following cotransfection of plasmids pNL4-3.Luc.R–E and 
pcDNA 3.1 EnvB/C, which contained the Env gene. These 
two proteins could be packaged into virus particles wherein 
the particle also contained luciferase. Such a particle is re-
ferred to as a pseudotype virus since it cannot replicate, but 
can infect HOS-CD4-CCR5 cells and the infection level 
could be detected by quantifying luciferase activity. The 
neutralization level could be evaluated by co-incubating 
blood samples and cotransfected supernatants and observing 
the change in luciferase. Our results showed that 0.5 g of 
VLPs could induce neutralizing antibody and that antibody 
levels increased as the immunizing dose increased. These 
antibodies could also counteract the infectivity of the 
pseudotype virus. The epitopes of the neutralizing antibod-
ies resided mainly in Pr55gag and gp120. Neutralization 
activity was highest in VLPs samples 12.5 g, and 25 g, as 
indicated by the low luciferase activity. Interestingly, 100 
g plasmid DNA could only elicit a lower level neutraliza-
tion activity than all VLPs amounts tested. It is also con-
ceivable that 12.5 ug is the optimal dose. The neutralization 
level in different dose groups tended to be similar at 1:1, 
1:2 and 1:4 dilution (Figure 8). 
3  Discussion 
The major advantage of a VLPs approach compared to 
live-attenuated virus is that VLPs express multiple viral 
epitopes that stimulate a diverse set of immune responses, 
without many of the deleterious effects of a live-attenuated 
virus. VLPs have the potential for activating both endoge-
nous and exogenous antigen processing pathways, leading 
to presentation of viral peptides by MHC class I and class II 
molecules. These multi-epitope vaccines are more likely 
than their single component counterparts to generate a 
broad-based immune response capable of clearing HIV-1 
immune evasion mutants. VLPs may be more cost efficient 
than co-inoculating multiple single gene vaccines for future 
Phase I clinical trials. Another advantage of VLPs com-
pared to single recombinant protein vaccines is the ability of 
VLPs to bind and enter cells expressing appropriate recep-
tors. HIV-1 VLPs are able to bind to CD4 and chemokine 
receptors via gp120, and to enter into professional antigen 
presenting cells such as macrophages and dendritic cells 
(both cell types express CD4 and CCR5). After infection, 
viral proteins can be processed and presented on MHC class 
I molecules, therefore promoting presentation to T cells by  
 
 
Figure 7  HIV-1 Ag-specific IFN- producing splenocytes are generated by VLP and DNA intramuscular vaccination. Each bar represents the average 
number of cells secreting IFN- per 106 cells. 
 
Figure 8  Detection of luciferase endpoints after pseudotype virus infection of HOS-CD4-CCR5 cells. Infected cells were co-incubated with blood samples 
and cotransfected supernatants. The expression of intracellular luciferase was measured as indicated. The values shown represent the means±standard devia- 
tion of three replicate cultures. 
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APCs. In addition, cell-free VLPs bound with antibodies 
can be taken up by phagocytic cells via Fc receptors, thus 
increasing MHC class II presentation. 
VLPs have been expressed in Baculovirus expression 
systems [25] and Saccharomyces cerevisiae [26,27]. These 
systems produce large amounts of particles from eukaryotic 
cells. However, they are usually limited to expressing only 
one gene, and therefore are not easily used to produce mul-
tigene VLPs. In addition, in order for particles to bud from 
yeast, the outer membrane needs to be removed. 
To overcome the above disadvantages, we first cotrans-
fected two plasmids, and used neomycin as stable screen 
marker. We then screened mammalian cell lines that could 
express the gagpol and env proteins with high efficiency. 
The gag protein readily packs into non-enveloped VLPs and 
the presence of the env protein can provide more antigenic 
determinants [22]. We took advantage of gag self-assembly 
and co-expressed gag and env to produce VLPs. Our ap-
proach demonstrated that this cell line could not only pro-
duce stable VLPs, but also secrete significant quantities of 
VLPs into the supernatant. The VLPs produced by our 
method without viral nucleic acid are not only safer, but 
also induce a strong humoral and cellular immune response, 
and provide a foundation for improving HIV vaccination. 
Because the recombinant Gagpol and Env proteins have 
similar structures to that of the wild HIV-1, additional work 
is required to fully understand how this approach could be 
used for advanced clinical applications. 
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